RAC need to be maximising the clinical data for Bisantrene. A first-in-class broad spectrum anti-cancer agent is very, very rare. With the patent clock ticking, RAC need to aggressively build clinical data package to maximize a commercial return.
I think this hesitation around other programs is partly to do with the absurd notion that RAC couldn't dose a patient.
Something that sounds perfect to me is a partnership/geographical licensing which expands the CPACS trial into a p1b/2 at multiple sites within a new geographical region as well as another clinical trial aiming to utilize the anti-cancer effects of Bisantrene alone or in combination.
RAC Price at posting:
$1.02 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)